We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
$50 for your first 3 months Get the print edition and steer from crisis to recovery
Add this topic to your myFT Digest for news straight to your inbox
Annual accounts underline huge investment parent company is making in UK-based team
Paradoxically, falling productivity in research strengthens the case for increasing spending on it
Disruption can be uncomfortable but there are big opportunities too
Discovery may dramatically speed up discovery of new drugs
OpenAI’s GPT-3 technology could significantly enhance human productivity and creativity
The technology company will need to persuade patients to hand over some of their most personal information
Mustafa Suleyman has been on a leave of absence at AI company
Alphabet unit’s ‘AlphaStar’ bots ranked above 99.8% of humans in complex game
Contracts with five trusts to share patient data are part of transfer of DeepMind Health
Mustafa Suleyman’s retreat suggests AI group’s autonomy has been curtailed by its parent
Staff costs rise rapidly at London research company owned by Alphabet
Full-year accounts show Deep Mind’s staff costs, an important measure, double
AI company’s model can give 48 hours’ warning of potentially fatal complications
Collaboration comes as AI researchers try to prove commercial worth to Alphabet
Device can diagnose a range of eye diseases in real time as accurately as the best specialists
Tech giants ramp up recruitment of university scientists with big salaries and resources
Kheiron’s test in England aimed at helping hospitals cope with shortage of radiologists
AlphaZero plays Go and chess at levels that defeat humans and the best existing programs
The transfer of the UK health unit to California raises privacy concerns
Relationship between British AI firm and US giant shifts
UK AI group that processes 1.6m NHS patient data also halts independent review panel
With potential uses in healthcare and finance, the technology promises to revolutionise computing
Clinical trials planned after early tests of DeepMind software
Review panel warns DeepMind will ultimately have to prove its value to parent
International Edition
